Overview

Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer

Status:
Completed

Trial end date:
2011-11-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the addition of enzastaurin to 5-FU (5-fluorouracil)/LV (leucovorin) plus bevacizumab in the maintenance of best response obtained with 6 cycles of first-line therapy consisting of 5-FU/LV + oxaliplatin (FOLFOX) or 5-FU/LV + irinotecan (FOLFIRI), plus bevacizumab in patients with Metastatic Colorectal Cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Eli Lilly and Company

Collaborator:

Roche Pharma AG

Treatments:

Bevacizumab
Fluorouracil
Leucovorin